Clinical Trials Logo

Lupus Erythematosus, Discoid clinical trials

View clinical trials related to Lupus Erythematosus, Discoid.

Filter by:

NCT ID: NCT00708916 Completed - Clinical trials for Discoid Lupus Erythematosus

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Start date: June 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.

NCT ID: NCT00691769 Completed - Clinical trials for Discoid Lupus Erythematosus

Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Start date: April 26, 2006
Phase:
Study type: Observational

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

NCT ID: NCT00625521 Completed - Clinical trials for Discoid Lupus Erythematosus

Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions

Start date: November 2006
Phase: Phase 2
Study type: Interventional

Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin. The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.

NCT ID: NCT00625157 Completed - Clinical trials for Discoid Lupus Erythematosus

Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)

Start date: n/a
Phase: Phase 2
Study type: Interventional

Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin. The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.

NCT ID: NCT00608673 Completed - Clinical trials for Discoid Lupus Erythematosus

Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

Start date: April 2006
Phase: N/A
Study type: Interventional

Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore, an alternative medication with the same efficacy, but without the side-effects is sought after. Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its efficacy in treating discoid lupus erythematosus has not been studied extensively yet. However studies performed till now show promising results. Long-term topical use of this medication has not shown any serious side-effects in other skin diseases. In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic choice, betamethasone valerate 0.1% cream, to see if pimecrolimus can be used as an alternative medication in treating discoid lupus erythematosus.

NCT ID: NCT00001680 Completed - Clinical trials for Discoid Lupus Erythematosus

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

Start date: October 1997
Phase: Phase 2
Study type: Interventional

The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing. Seventeen patients with two similar lesions will have lesions randomized to receive either intervention or placebo therapy.